Take part in

The 2nd Olea Innovators Awards

Theme : Innovative MRI medical imaging techniques for diagnosis and follow up of devastating diseases.


Submitted projects will be assessed by a jury of experts in Radiology and/or specialists in innovative projects’ development.

The winners will be awarded great prizes!

For the TECHNICAL INDUSTRIALIZATION category: potential to study commercialization of their innovation with Olea Medical®.

For the INNOVATION INCUBATOR category: the 3 winning projects will be awarded a research grant of 10,000 euros.

Applications will be received by Olea Medical® innovation department, by june 30th., 2017.

The award ceremony will be held at the Journées Françaises de la Radiologie, in Paris, in October 2017.

Partner of Olea Innovators 2nd edition:

How to apply ?

1. Download your registration form

Olea Innovators application file

Download Acrobat Reader for free to fill in the application form.

2. Complete and return the applications form to Olea Medical®

Pack your illustrations (graphics, pictures, drawings, or designs) into a unique compressed ZIP or RAR file.

3. Agree with Olea Medical Privacy Policy with respect to candidates
Consult Olea Medical "Privacy Statement" regarding personal information
Between the undersigned:

OLEA MEDICAL, a limited liability company with its registered office located at 93 avenue du Sorbier, 13600 La Ciotat (hereafter, “Olea Medical”); on the one hand, and, The Candidate (as designated by the signature), on the other hand, also referred to individually as a “Party” and collectively as the “Parties.”WHEREAS:(A) The Candidate wishes to participate in the “Olea Innovators” Contest, the rules for which he/she has reviewed and accepted, and for this he/she must share the Confidential Information with Olea;(B) Consequently, in this Confidentiality Agreement (hereafter, the “Agreement”), the Parties wish to set the rules relating to the disclosure, use and protection of this information.

1. Confidential Information.In the Agreement, the term “Confidential Information” designates any information or data communicated in connection with the Agreement by one Party to the other Party in any manner whatsoever and in any medium whatsoever.

The Confidential Information may be communicated in writing, orally or by any other means, in particular by video, computer files and photography or by the material transmission of samples, technical specifications, plans, drawings and models, with this list not being exhaustive.

It is moreover expressly agreed that any information to which the addressee Party may have access or which it may receive at the time of visits to the premises of the issuing Party shall be considered and treated as Confidential Information.

In addition, the Parties expressly agree that any information which may be obtained, in particular, by means of tests, studies, analyses of any samples, formulas, processes, sketches, photographs, plans, maps, drawings, specifications, images, reports, know-how, inventions and ideas, whether patentable or not, components or computer equipment provided to the addressee Party by the issuing Party shall be considered to be Confidential Information.

2. Ownership of the Confidential Information.

This Confidential Information shall remain the property of the issuing Party and must be considered to be strictly confidential, without the necessity to specify this or to mark this information as confidential. Notwithstanding any other provision of this Agreement, the Party issuing the Confidential Information shall be considered to be the sole holder of all rights to this Confidential Information.

3. Non-disclosure and protection of Confidential Information.

Each Party receiving the Confidential Information undertakes for a duration of three (3) years following receipt thereof:

a) To protect this Confidential Information and to maintain it strictly confidential and to treat it with the same degree of care and protection as it provides to its own Confidential Information;

b) To disclose this Confidential Information internally only to the members of its personnel who have a need to know it and to inform them of the confidential character of this and the obligations related thereto;

c) Not to copy, reproduce or duplicate it in whole or in part, or to transmit the Confidential Information to third parties without the prior written consent of the issuing Party.

4. Limitation on the use of the Confidential Information.

The use of the Confidential Information by the addressee Party is strictly limited to the assessment requirements specified in the Preamble.

5. Non-Confidential Information.

The provisions of Articles 3 and 4 above do not apply to Confidential Information for which the addressee Party can provide proof in writing that:

a) it entered the public domain prior to or after being disclosed, but in the latter case, in the absence of any fault attributable to it or b) the Confidential Information was already known to it at the time of its disclosure or c) it was disclosed by a third party in a legal manner, without restriction or violation of any confidential obligation or d) that it was the result of work and independent internal development carried out by the addressee Party, in the absence of any fault which may be attributable to it.

6. The absence of Guarantee.

The Party holding the disclosed Confidential Information does not guarantee either the accuracy, the completeness or the utility of it.

7. Absence of rights to the Confidential Information.

The disclosure of Confidential Information by one Party to the other Party in connection with the Agreement may not, in any event, be interpreted as granting an express or implicit right of any sort whatsoever to the addressee Party with regard to this Confidential Information, particularly as concerns any intellectual, industrial, or literary or artistic rights belonging to the other Party.

8. Absence of Future Obligations.

No provision of this Agreement may be interpreted as obliging one or the other of the Parties to establish a contractual connection with the other in the future.

9. State Control.

To the extent that the Confidential Information is subject to the laws and regulations concerning export control by the authorities of the issuing Party’s country, the addressee Party undertakes to comply therewith.

10. Any Confidential Informationclassified as “Defense Secrets” and disclosed by one of the Parties in connection with this Agreement must be identified as such by the issuing Party as the time of disclosure. The disclosure, protection and use of this Confidential Information must comply with the security procedures required by all of the public authorities concerned.

11. Return of the Confidential Information.

The Party receiving the Confidential Information, regardless of its condition or the medium used, must return this to the issuing Party or destroy this according to the instructions received, without delay and at first request.

12. Entire Agreement. Modifications.

a) All of the provisions of this Agreement constitute the entire agreement between the Parties with regard to its subject and supersede and cancel any prior declarations, negotiations, commitments, oral or written communications, acceptances, understandings and prior agreements between the Parties concerning the provisions to which this Agreement applies or for which it provides.

b) The Agreement may not be assigned or transferred in whole or in part by any means whatsoever by one Party to a third party without the prior written consent of the other Party.

c) The Agreement may only be amended or modified by an amendment signed by the duly authorized representatives of each Party.

13. Applicable Law. Jurisdiction.

In the absence of an amicable settlement between the Parties, any disagreements resulting from this Agreement shall be brought before the appropriate courts of the Court of Appeals of Provence, with French law being applicable.

14. Notifications.

All notifications must be transmitted to the following addresses and persons, which may be modified by advance written notice: Olea Medical S.A., 93 avenue du Sorbier, 13600 La Ciotat, France To the attention of: Mr. Fayçal DJERIDANE Name and address of the Candidate:

15. Entry into Force.

The Agreement shall enter into force as from the date of delivery of the Candidate’s application for the “Olea Innovators” Contest.

4. Read the full contest rules

Download the complete competition rules

*Mandatory fields